Rhythm Pharmaceuticals said on Friday the U.S. Food and Drug Administration has extended the review period for expanded approval of its drug, Imcivree, as a treatment for a rare form of obesity.
https://www.yahoo.com/news/finance/news/rhythm-forced-wait-imcivree-expansion-170750163.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.